https://www.selleckchem.com/pr....oducts/Staurosporine
5% for patients with pneumonia (P less then 0.001), and from 53.4% to 65.7% for patients with acute bronchitis (P less then 0.001). Use of CXR increased for patients with acute bronchitis from 3.1% to 5.1% (P less then 0.001). Use of microbiological tests increased for patients with pneumonia, from 1.8% to 5.1% (P less then 0.001). The antibiotic prescription rate decreased from 18.6 to 8.2 per 1000 inhabitants per year for patients with acute bronchitis, but did not change for patients with pneumonia. CONCLUSION Use of CRP and mi